2026-06-14T06:44:28Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/79822024-09-27T09:42:30Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Lara-Pezzi, Enrique author Menasché, Philippe author Trouvin, Jean-Hugues author Badimón, Lina author Ioannidis, John P A author Wu, Joseph C author Hill, Joseph A author Koch, Walter J author De Felice, Albert F author de Waele, Peter author Steenwinckel, Valérie author Hajjar, Roger J author Zeiher, Andreas M author 2015-02 Heart failure (HF) remains a major cause of death and hospitalization worldwide. Despite medical advances, the prognosis of HF remains poor and new therapeutic approaches are urgently needed. The development of new therapies for HF is hindered by inappropriate or incomplete preclinical studies. In these guidelines, we present a number of recommendations to enhance similarity between HF animal models and the human condition in order to reduce the chances of failure in subsequent clinical trials. We propose different approaches to address safety as well as efficacy of new therapeutic products. We also propose that good practice rules are followed from the outset so that the chances of eventual approval by regulatory agencies increase. We hope that these guidelines will help improve the translation of results from animal models to humans and thereby contribute to more successful clinical trials and development of new therapies for HF. J Cardiovasc Transl Res. 2015; 8(1):3-22 10.1007/s12265-015-9606-8 1937-5395 1937-5387 Journal of cardiovascular translational research 25604959 http://hdl.handle.net/20.500.12105/7982 Guidelines for translational research in heart failure